Analysts generally think investors should stand pat on Hospira, with eight of 14 analysts rating it hold.
Hospira is the global leader of the generic injectables industry with 37% market share as of June 2012.
FORBES: Patient Investors Will Find The Right Prescription In Hospira
The prediction may not be terribly surprising, given the extent of the issues that Hospira has faced.
FORBES: Hospira May Get A Consent Decree For Its Manufacturing Problems
Tenet Healthcare jumped 10.1% to set the pace, while Hospira, a provider of generic injectable drugs, rallied 4.1%.
FORBES: Stocks Slump As Market Reacts To Obama Win, Draghi's Germany Warning
Many Hospira meds now appear on the FDA shortages list ( see this).
FORBES: Hospira May Get A Consent Decree For Its Manufacturing Problems
The majority of analysts think investors should stand pat on Hospira, with nine of 13 analysts rating it hold.
Its only American producer, a company called Hospira, disliked its use in executions and ceased making it in January.
In devices, Hospira commands a 17% market share as the number two player in the industry, behind the market leader, CareFusion.
FORBES: Patient Investors Will Find The Right Prescription In Hospira
Hospira (HSP) reports its fourth quarter earnings on Wednesday, February 13, 2013.
Wall Street is expecting lower profit for Hospira (HSP) when the company reports its third quarter results on Wednesday, November 7, 2012.
Hospira ( HSP) operated as the hospital products business of Abbott Laboratories until it was spun off into a stand-alone entity in 2004.
FORBES: Patient Investors Will Find The Right Prescription In Hospira
The consensus estimate is 54 cents per share, up 5.9% from a year ago when Hospira reported earnings of 51 cents per share.
Hospira reported profit of 94 cents a year ago, but the consensus estimate calls for earnings per share of 49 cents this time around.
Analysts are looking for decreased profit for Hospira (HSP) when the company reports its results for the second quarter on Wednesday, August 1, 2012.
Hospira disclosed that the FDA has issued yet another warning letter, but this time to a plant that was previously not on the agency radar.
Service contracts on their installed devices usually last around three years providing Hospira with a recurring revenue base not only for services, but also for their injectable products.
FORBES: Patient Investors Will Find The Right Prescription In Hospira
After speaking with FDA manufacturing and quality control consultants, and senior execs from other generic injectable makers, Malhotra believes the Hospira violations meet FDA criteria for entering a consent decree.
FORBES: Hospira May Get A Consent Decree For Its Manufacturing Problems
For the next few months, we plan to use this space to share our insights on decision effectiveness, as well as some practical examples from companies such as ABB, Ford Motor Company, MetLife and Hospira.
应用推荐